KC
MRNA icon

Knuff & Co’s Moderna MRNA Stock Holding History

Knuff & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,140
Closed -$174K – 132
2025
Q1 		$174K Buy
6,140
+2,263
+58% +$80.3K 0.06% 92
2024
Q4 		$161K Sell
3,877
-855
-18% -$40.9K 0.05% 104
2024
Q3 		$316K Buy
4,732
+244
+5% +$22.4K 0.1% 84
2024
Q2 		$533K Sell
4,488
-1,003
-18% -$127K 0.17% 70
2024
Q1 		$585K Sell
5,491
-2,889
-34% -$291K 0.2% 66
2023
Q4 		$833K Sell
8,380
-12,417
-60% -$1.04M 0.3% 56
2023
Q3 		$2.15M Buy
20,797
+3,644
+21% +$406K 0.86% 34
2023
Q2 		$2.08M Buy
17,153
+246
+1% +$32.8K 0.78% 35
2023
Q1 		$2.6M Sell
16,907
-867
-5% -$143K 1.03% 31
2022
Q4 		$3.19M Buy
17,774
+536
+3% +$87.6K 1.36% 27
2022
Q3 		$2.04M Sell
17,238
-1,026
-6% -$156K 0.96% 31
2022
Q2 		$2.61M Buy
18,264
+78
+0.4% +$11.1K 1.17% 24
2022
Q1 		$3.13M Buy
18,186
+744
+4% +$125K 1.14% 27
2021
Q4 		$4.43M Buy
17,442
+367
+2% +$107K 1.37% 23
2021
Q3 		$6.57M Sell
17,075
-105
-0.6% -$38.7K 2.46% 12
2021
Q2 		$4.04M Buy
17,180
+12,038
+234% +$2.15M 1.5% 23
2021
Q1 		$673K Buy
+5,142
New +$745K 0.29% 63

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Knuff & Co's MRNA Position: Q2 2025 in Review

Knuff & Co sold out of Moderna (MRNA) in Q2 2025, closing a stake of 6,140 shares — an estimated $174K sold.

Knuff & Co first reported a position in MRNA in Q1 2021 and held it in 17 quarters. The position peaked at $6.57M in Q3 2021. 675 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Knuff & Co reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • Knuff & Co sold 6,140 Moderna shares in Q2 2025, an estimated $174K.
  • Knuff & Co first reported a position in Moderna in Q1 2021 and held it in 17 quarters.
  • Knuff & Co's Moderna position peaked at $6.57M in Q3 2021.
  • 675 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Knuff & Co's 13F filing for Q2 2025, filed 13 Aug 2025.